Summary
The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m–2 day–1 for 3 days and cisplatin 100 mg m–2 on day 1, given by 2-h intravenous infusion, administered every 21 days. Twelve patients had a well-differentiated and 41 a poorly differentiated neuroendocrine tumour. Toxicity of treatment was assessed in 50 patients and efficacy in 52 patients. Among the 11 patients with a well-differentiated tumour evaluable for tumoural response, only one (9.4%) had a partial response for 8.5 months. Forty-one patients with a poorly differentiated tumour showed an objective response rate of 41.5% (four complete and 13 partial responses); the median duration of response was 9.2 months, the median overall survival 15 months and the median progression-free survival 8.9 months. Haematological grade 3–4 toxicity was observed in 60% of the cases with one treatment-related death, digestive grade 3–4 toxicity in 40% and grade 3 alopecia was constant. No severe renal, hearing and neurological toxicities were observed (grade 1 in 6%, 14%, 72% respectively and no grade >1). We confirm that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination. However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baudin, E, Gigliotti, A, Ducreux, M, Ropers, J, Comoy, E, Sabourin, JC, Bidart, JM, Cailleux, AF, Bonacci, R, Ruffie, P & Schlumberger, M (1998). Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78: 1102–1107.
Baudin, E, Bidart, JM, Rougier, P, Lazar, V, Ruffie, P, Ropers, J, Ducreux, M, Troalen, F, Sabourin, JC, Comoy, E, Lasser, P, DeBaere, T & Schlumberger, M (1999). Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab 84: 69–75.
Gould, VE, Linnoila, RI, Memoli, VA & Warren, WH (1983). Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu 18: 287–330.
Greenberg, RS, Baumgarten, DA, Clark, WS, Isacson, P & McKeen, K (1987). Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 60: 2476–2483.
Hainsworth, JD, Johnson, MH & Greco, A (1988). Poorly differentiated neuroendocrine carcinoma of unknown primary site. Ann Intern Med 109: 364–371.
Janson, ET, Holmberg, L, Stridsberg, M, Eriksson, B, Theodorsson, E, Wilander, E & Oberg, K (1997). Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8: 685–690.
Johnson, LA, Lavin, P, Moertel, CG, Weiland, L, Dayal, Y, Doos, WG, Geller, SA, Cooper, HS, Nime, F, Masse, S, Simson, IW, Sumner, H, Folsch, E & Engstrom, P (1983). Carcinoids: the association of histologic growth pattern and survival. Cancer 51: 882–889.
Kaplan, EL & Meier, P (1958). Non-parametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481.
McDermott, EW, Guduric, B & Brennan, MF (1994). Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81: 1007–1009.
Mantel, N & Haenszel, W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
Miller, AB, Hoogstraten, B, Staquet, M & Winkler, A (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Modlin, IM & Sandor, A (1997). An analysis of 8305 cases of carcinoid tumors. Cancer 79: 813–829.
Moertel, CG, Kvols, LK, O'Connell, MJ & Rubin, J (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68: 227–232.
Oberg, K (1994). Treatment of neuroendocrine tumors. Cancer Treat Rev 20: 331–355.
Pelley, RJ & Bukowski, RM (1997). Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 9: 68–74.
Rindi, G, Bordi, C, Rappel, S, Larosa, S, Stolte, M & Solcia, E (1996). Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20: 168–172.
Seitz, J, Perrier, H, Giovannini, M, Monges, G, Fourdan, O, Barrière, N & Viens, P (1995). Cancers neuroendocrines anaplasiques avancés: intérêt de l’association VP16-CDDP. Bull Cancer 82: 433
Staren, ED, Gould, VE, Warren, WH, Wool, NL, Bines, S, Baker, J, Bonomi, P, Roseman, DL & Economou, SG (1988). Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery 104: 1080–1089.
Warren, WH, Faber, LP & Gould, VE (1989). Neuroendocrine neoplams of the lung: a clinicopathologic update. J Thorac Cardiovasc Surg 98: 321–332.
Williams, ED & Sandler, M (1963). The classification of carcinoid tumors. Lancet 1: 238
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mitry, E., Baudin, E., Ducreux, M. et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81, 1351–1355 (1999). https://doi.org/10.1038/sj.bjc.6690325
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690325
Keywords
This article is cited by
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications (2023)
-
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
Nature Reviews Clinical Oncology (2023)
-
Review of Merkel cell carcinoma with solitary pancreatic metastases mimicking primary neuroendocrine tumor of the pancreas
Clinical Journal of Gastroenterology (2023)
-
Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma
Journal of Gastrointestinal Cancer (2023)
-
Bone metastatic cancer of unknown primary at initial presentation
Clinical and Translational Oncology (2023)